RET fusion

RET gene fusions detected by sequencing or FISH; used as a predictive marker for selective RET inhibitors in non-small cell lung, thyroid and other solid tumors.

CI-BIO-00000022RET graph →NCIt C131069 Tumor-agnostic · 3 approval rows

Also calledRET rearrangement · RET fusion-positive · KIF5B-RET · CCDC6-RET

Tissue-agnostic indications

Approval rows flagged tumor-agnostic (3)

Selpercatinib EU EMA · Feb 11, 2021 · drug in derived setRegulatory approved
Selpercatinib US FDA · Apr 10, 2024 · drug + indication textRegulatory approved
Selpercatinib US FDA · May 8, 2020 · drug + indication textRegulatory approved

The flag is the source's (openFDA label text), never inferred; the full indication text of each row is in the Approvals section below.

Derived

Associated cancers (10)

Cancers mapped in ACCEPTED CIViC predictive, prognostic or diagnostic items whose variant (molecular markers) or gene (gene-level markers) is in this biomarker's scope. Counts by type and native level; each row links to the cancer's evidence tab.

Computedrule biomarker-links-v1

Cancer	Items	Predictive	Prognostic	Diagnostic	Levels A / B / C / D / E
Thyroid Gland Medullary Carcinoma	15	13	2	—	3 / 6 / 3 / 3 / 0
Lung Non-Small Cell Carcinoma	8	8	—	—	1 / 4 / 3 / 0 / 0
Lung Adenocarcinoma	4	3

Derived

Drugs with predictive evidence (12)

Therapies named in in-scope PREDICTIVE CIViC items, plus targets of PREDICTS_RESPONSE_TO knowledge edges from in-scope variants. Sensitivity and resistance are counted separately and never merged into a verdict.

Computedrule biomarker-links-v1

Drug	CIViC items	Sensitivity	Resistance	Best level	Edges (S / R)	Cancer context
SelpercatinibSmall Molecule	18	16	2	A	19 / 6	Lung Non-Small Cell Carcinoma, Malignant Neoplasm, Malignant Thyroid Gland Neoplasm, Solid Neoplasm +2
VandetanibSmall Molecule	5	5	—	B	5 / 0	Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Malignant Breast Neoplasm
PralsetinibSmall Molecule	3	3	—	A	3 / 0	Lung Non-Small Cell Carcinoma, Malignant Neoplasm, Malignant Thyroid Gland Neoplasm
CabozantinibSmall Molecule	2	2	—	B	2 / 0	Lung Adenocarcinoma, Thyroid Gland Medullary Carcinoma
MotesanibSmall Molecule	2	—	2	D	0 / 2	Thyroid Gland Medullary Carcinoma
AgerafenibSmall Molecule	1	1	—	C	1 / 0	Malignant Colorectal Neoplasm
AlectinibSmall Molecule	1	1	—	C	1 / 0	Lung Non-Small Cell Carcinoma
EverolimusSmall Molecule	1	1	—	C	1 / 0	Lung Adenocarcinoma
JAK2 Inhibitor AZD1480	1	1	—	D	1 / 0	Thyroid Gland Medullary Carcinoma
NintedanibSmall Molecule	1	1	—	C	1 / 0	Lung Non-Small Cell Carcinoma
SorafenibSmall Molecule	1	1	—	B	1 / 0	Thyroid Gland Medullary Carcinoma
SunitinibSmall Molecule	1	1	—	C	1 / 0	Papillary Adenocarcinoma

Curatedcivic items and knowledge edges as curated at the source.

Curated evidence

Predictive evidence items (35)

ACCEPTED CIViC predictive items in scope, grouped by molecular profile and therapy with native level, direction and cancer context. 50 per page.

civicCuratedShowing 1–35 of 35 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
RET Fusion10
Cabozantinib	Lung Adenocarcinoma	Predictive	B	Supports Sensitivity Response	3	accepted	EID4847 RET rearrangements are found in 1-2% of non-small-cell lung cancers. Cabozantinib is a multikinase inhibitor with activity against RET that produced a 10% overall response in unselected patients with … (full text at CIViC) PMID 27825636 · Drilon et al., 2016 · Open in CIViC	civic
Alectinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	C	Supports Sensitivity Response	3	accepted	EID4850 Alectinib is an anaplastic lymphoma kinase tyrosine kinase inhibitor (TKI) that also has anti-RET activity in vitro. 4 patients with metastatic RET-rearranged NSCLC were identified. 3 of 4 had receive… (full text at CIViC) PMID 27544060 · Lin et al., 2016 · Open in CIViC	civic
Pralsetinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	A	Supports Sensitivity Response	4	accepted	EID11233 In an open-label, phase 1/2 trial on 87 patients with NSCLC including RET-fusion were given 400 mg once-daily oral pralsetinib, with the outcome measured as overall response rate. Overall responses we… (full text at CIViC) PMID 34118197 · Gainor et al., 2021 · Open in CIViC	civic
Selpercatinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	4	accepted	EID7066 In this phase 1 trial, 57 patients with RET fusion- or mutation positive cancers were treated in 7 dose levels. Among patients with RET-Fusion positive NSCLC, objective response rates were 65% (n = 17… (full text at CIViC) Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	4	accepted	EID8850 Patients with RET-fusion positive non-small cell lung cancer were enrolled in this phase 1-2 trial of RET inhibitor selpercatinib. Among 105 consecutively enrolled patients who had previously received… (full text at CIViC) PMID 32846060 · Drilon et al., 2020 · Open in CIViC	civic
Vandetanib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	3	accepted	EID4848 RET rearrangements involving RET are found in about 1% of NSCLC and define a unique molecular subset. This study was a multi-center, open-label, phase II clinical trial to examine the safety and effi… (full text at CIViC) PMID 27803005 · Lee et al., 2017 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	3	accepted	EID4849 We aimed to assess the efficacy and safety of vandetanib in patients with advanced RET-rearranged NSCLC. In this open-label, multicentre, phase 2 trial (LURET), patients with advanced RET-rearranged N… (full text at CIViC) PMID 27825616 · Yoh et al., 2017 · Open in CIViC	civic
Pralsetinib	Malignant Thyroid Gland Neoplasm	Predictive	A	Supports Sensitivity Response	4	accepted	EID11234 In a phase 1/2, open-label trial, 122 patients with RET-mutant medullary cancer and 20 with RET-fusion positive thyroid cancer were administered 400 mg daily oral pralsetinib. The overall response rat… (full text at CIViC) PMID 34118198 · Subbiah et al., 2021 · Open in CIViC	civic
Selpercatinib	Malignant Thyroid Gland Neoplasm	Predictive	A	Supports Sensitivity Response	4	accepted	EID8852 In this phase 1/2 trial (NCT03157128), patients with RET altered thyroid cancers were enrolled to receive the highly selective RET inhibitor selpercatinib. Among 19 patients with previously treated RE… (full text at CIViC) PMID 32846061 · Wirth et al., 2020 · Open in CIViC	civic
〃	Thyroid Gland Papillary CarcinomaALIAS	Predictive	B	Supports Sensitivity Response	4	accepted	EID7069 In this phase 1 trial, patients with RET-fusion or mutation positive cancers were treated with the selective RET-inhibitor selpercatinib (LOXO-292). Among the 6 patients with RET-fusion positive papil… (full text at CIViC) Open in CIViC	civic
RET Fusion2
Everolimus + VandetanibCombination	Lung Adenocarcinoma	Predictive	C	Supports Sensitivity Response	2	accepted	EID1622 Case report of a 74-year old woman with EGFR- and ALK-negative lung adenocarcinoma. FISH identified a deletion of 5'RET (FISH, indicating RET-gene rearrangement) and genomic testing confirmed a fusion… (full text at CIViC) PMID 25982012 · Subbiah et al., 2015 · Open in CIViC	civic
Vandetanib	Lung Adenocarcinoma	Predictive	C	Supports Sensitivity Response	2	accepted	EID698 A case study of a patient with EGFR, KRAS, BRAF, HER2, ALK, ROS1 and MET negative adenocarcinoma of the lung. FISH analysis revealed a KIF5B-RET fusion. The RET inhibitor Vandetanib led to remission i… (full text at CIViC) PMID 23584301 · Gautschi et al., 2013 · Open in CIViC	civic
RET Fusion2
Nintedanib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	C	Supports Sensitivity Response	2	accepted	EID1601 Case report of a 60-year old woman with lung adenocarcinoma. After negative testing for EGFR mutations and ALK translocations and failure of platinum-based chemotherapy she was enrolled on a nintedani… (full text at CIViC) PMID 26787234 · Takeda et al., 2016 · Open in CIViC	civic
Agerafenib	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	C	Supports Sensitivity Response	3	accepted	EID7480 A patient with right-sided, MSI-High and CCDC6-RET positive metastatic colorectal cancer showed complete response to the selective RET inhibitor RXDX-105. The patient remained progression-free after 1… (full text at CIViC) PMID 29538669 · Pietrantonio et al., 2018 · Open in CIViC	civic
RET Fusion + RET G810C + RET G810R + RET G810S1
Selpercatinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	C	Supports Resistance	4	accepted	EID8195 A 61-year old patient with KIF5B-RET fusion positive NSCLC received clinical benefit from selpercatinib treatment initially. ctDNA surveillance showed the emergence of RET G810S 3 months after the sta… (full text at CIViC) PMID 31988000 · Solomon et al., 2020 · Open in CIViC	civic
RET Overexpression2
Vandetanib	Malignant Breast Neoplasm	Predictive	D	Supports Sensitivity Response	2	accepted	EID740 Vandetanib was tested in 4 murine models of patient-derived xenografts. In xenografts with high expression of EGFR or RET, vandetanib led to tumor regression, in those without high expression, vandeta… (full text at CIViC) PMID 26686064 · Hatem et al., 2016 · Open in CIViC	civic
Sunitinib	Papillary Adenocarcinoma	Predictive	C	Supports Sensitivity Response	3	accepted	EID1518 A 78-year-old man presented with oral papillary adenocarcinoma and lung metastases that were refractory to standard treatment. Tumor sequencing showed increased MAPK activity due to RET over-expressi… (full text at CIViC) PMID 20696054 · Jones et al., 2010 · Open in CIViC	civic
RET M918T7
Pralsetinib + SelpercatinibSubstitutes	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	4	accepted	EID11867 Ba/F3 transformed cells harboring RET D898_E901del, T930K, T930P, or M918T mutations were shown to be sensitive to the highly selective RET inhibitors selpercatinib (LOXO-292) and pralsetinib (BLU-667… (full text at CIViC) PMID 32284345 · Zhao et al., 2020 · Open in CIViC	civic
Selpercatinib	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	2	accepted	EID11876 Preclinical data demonstrated Ba/F3 cells transformed with RET p.M918T were sensitive to selpercatinib with an IC50 of 5nM. M918T was included as a positive control for other variants that were being … (full text at CIViC) PMID 37376747 · Szymczak et al., 2023 · Open in CIViC	civic
Cabozantinib
RET C618R1
Selpercatinib	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	2	accepted	EID11877 Preclinical data demonstrated Ba/F3 cells transformed with RET p.C618R were sensitive to selpercatinib with an IC50 of 3.5nM. PMID 37376747 · Szymczak et al., 2023 · Open in CIViC	civic
RET Mutation + RET Fusion2
Selpercatinib	Solid NeoplasmCURATED_BROADER	Predictive	A	Supports Sensitivity Response	4	accepted	EID12056 As part of this trial, 27 pediatric patients (aged 2-20), harbouring, RET-mutant medullary thyroid cancer (MTC, n = 14), RET fusion-positive papillary thyroid cancer (RTC, n=10), or other tumour types… (full text at CIViC) Open in CIViC	civic
〃	Solid NeoplasmCURATED_BROADER	Predictive	A	Supports Sensitivity Response	5	accepted	EID12708 In the phase 1/2 trial LIBRETTO-121 (NCT03899792), for patients 0.5-21 yrs old with advanced RET-altered solid tumors, dosing started at 92 mg/m2 twice a day of Selpercatinib. Patients had RET-mutant… (full text at CIViC) Open in CIViC	civic
RET C634W1
Motesanib	Thyroid Gland Medullary CarcinomaALIAS	Predictive	D	Supports Resistance	3	accepted	EID75 Medullary thyroid cancer cells with RET C634W mutation are insensitive to motesanib, compared to wild-type RET. PMID 21422803 · Coxon et al., 2012 · Open in CIViC	civic
RET Mutation3
Selpercatinib	Thyroid Gland Medullary CarcinomaALIAS	Predictive	A	Supports Sensitivity Response	4	accepted	EID8851 In this international phase 1/2 trial (NCT03157128), 55 RET-mutant medullary thyroid cancer patients who had previously received the multi-kinase inhibitors vandetanib and/or cabozantinib received th… (full text at CIViC) PMID 32846061 · Wirth et al., 2020 · Open in CIViC	civic
〃	Thyroid Gland Medullary CarcinomaALIAS	Predictive	A	Supports Sensitivity Response	5	accepted	EID12157 In this phase III trial, 291 patients (12 years or older) with medullary thyroid cancer harbouring RET mutations were enrolled. Patients were randomized in a 2:1 ratio to receive selpercatinib (n=193)… (full text at CIViC) PMID 37870969 · Hadoux et al., 2023 · Open in CIViC	civic
〃	Thyroid Gland Medullary Carcinoma
RET E632_L633del1
Selpercatinib	Thyroid Gland Medullary CarcinomaALIAS	Predictive	B	Supports Sensitivity Response	3	accepted	EID11875 Among 319 medullary thyroid cancer patients enrolled in the LIBRETTO-001 trial, 9 patients harbored the RET p.E632_L633del mutation (c.1894_1899delGAGCTG) in their tumor. After treatment with the sel… (full text at CIViC) PMID 37376747 · Szymczak et al., 2023 · Open in CIViC	civic
RET M918T + RET V804M1
Selpercatinib	Thyroid Gland Medullary CarcinomaALIAS	Predictive	C	Supports Sensitivity Response	4	accepted	EID6950 After progressing on 6 multi-kinase inhibitor (MKI) regimens (including sorafenib , vandetanib, cabozantinib, MGCD-516, RXDX-105, and vandetanib plus everolimus ), a metastatic medullary thyroid cance… (full text at CIViC) PMID 29912274 · Subbiah et al., 2018 · Open in CIViC	civic
RET V804M1
Selpercatinib	Thyroid Gland Medullary CarcinomaALIAS	Predictive	C	Supports Sensitivity Response	3	accepted	EID7068 In this phase 1 trial, 57 patients were treated with the selective RET Inhibitor selpercatinib (LOXO-292). A 57-year-old male with a hereditary RET V804M gatekeeper mutation treated with 3 prior multi… (full text at CIViC) Open in CIViC	civic
RET G810S + RET M918T1
Selpercatinib	Thyroid Gland Medullary CarcinomaALIAS	Predictive	C	Supports Resistance	3	accepted	EID8196 In two out of three patients with MTC treated in a phase1/2 trial, the RET G810 mutation emerged in ctDNA together with an acquired resistance after initial response to selpercatinib. PMID 31988000 · Solomon et al., 2020 · Open in CIViC	civic

Regulatory

Approvals mentioning the linked drugs (164)

Approval records of the derived drug set, plus records whose indication text names this biomarker. Each record names its authority, jurisdiction, indication text and status — a drug approved in one jurisdiction for one indication is not 'approved' in general, and an approval listed here is not necessarily restricted to this biomarker.

Computedrule biomarker-links-v1

emaRegulatory50 approval records from 3 sources (hover a row badge for its dataset) · authority, jurisdiction and indication text as published.

Drug	Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
Selpercatinib	EU EMA	Tumor-agnostic	Retsevmo as monotherapy is indicated for the treatment of adults with: advanced RET fusion positive non small cell lung cancer (NSCLC) not previously treated with a RET inhibitor. For biomarker-based patient selection, see section 4.2.  Retsevmo as monotherapy is indicated for the treatment of adults and paediatric patients 2  years of age and older with: advanced RET fusion positive thyroid cancer who are radioactive iodine-refractory (if radioactive iodine is appropriate) . For biomarker-based patient selection, see section 4.2. advanced RET mutant medullary thyroid cancer (MTC) . For biomarker-based patient selection, see section 4.2. advanced RET fusion positive solid tumours, when treatment options not targeting RET provide limited clinical benefit, or have been exhausted (see sections  4.4 and 5.1). For biomarker-based patient selection, see section 4.2.	approved	Feb 11, 2021	ema
Selpercatinib	US FDA	Tumor-agnostic	Adult and pediatric patients 2 years of age and older with locally advanced or metastatic solid tumors with a RET gene fusion, as detected by an FDA-approved test, that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options	approved	Apr 10, 2024	openfda
Selpercatinib

Health Canada DIN rows carry no indication text and only match by drug.

Clinical trials

Active trials (78)

Trials with an active ClinicalTrials.gov status, an intervention mapped to a derived drug and a condition mapped to an associated cancer. 37 recruiting · 16 active phase 3 · 394 in any status. Most recently updated first, 50 per page.

Computedrule biomarker-links-v1

clinicaltrialsPublishedShowing 1–50 of 78 active studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03899155	Pan Tumor Rollover Study	recruiting	Phase 2	1,500	Bristol-Myers SquibbINDUSTRY	38	Sep 23, 2026	clinicaltrials
NCT07405164	Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)	recruiting	Phase 3	450	Merck Sharp & Dohme LLCINDUSTRY	22	Sep 23, 2026	clinicaltrials
NCT07822880	A Study of Selpercatinib (LY3527723) in Participants With Rearranged During Transfection (RET)-Altered Cancers in India	not yet recruiting	Phase 4	30	Eli Lilly and CompanyINDUSTRY	1	Sep 23, 2026	clinicaltrials
NCT02693535	TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer(TAPUR)	recruiting	Phase 2	4,200	American Society of Clinical OncologyOTHER	2	Sep 22, 2026	clinicaltrials
NCT05508906	Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer	active not recruiting	Phase 1	190	Olema Pharmaceuticals, Inc.INDUSTRY	2	Sep 15, 2026	clinicaltrials
NCT04302025	A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)(NAUTIKA1)	recruiting	Phase 2	99	Genentech, Inc.INDUSTRY	1	Sep 10, 2026	clinicaltrials
NCT01708954	Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer	active not recruiting	Phase 2	125	National Cancer Institute (NCI)NIH	1	Sep 9, 2026	clinicaltrials
NCT05502315	Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer(CANOPY)	active not recruiting	Phase 2	47	Rana McKay, MDOTHER	1	Sep 8, 2026	clinicaltrials
NCT06862869	Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy	recruiting	—	800	Hoffmann-La RocheINDUSTRY	1	Sep 8, 2026	clinicaltrials
NCT04589845	Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study	active not recruiting	Phase 2	920	Hoffmann-La RocheINDUSTRY	23	Sep 4, 2026	clinicaltrials
NCT03178552	A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)(B-FAST)	active not recruiting	Phase 2 / Phase 3	1,000	Hoffmann-La RocheINDUSTRY	27	Sep 3, 2026	clinicaltrials
NCT05536141	A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors(ARC-20)	recruiting	Phase 1	362	Arcus Biosciences, Inc.INDUSTRY	4	Aug 31, 2026	clinicaltrials
NCT02867592	Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors	active not recruiting	Phase 2	109	National Cancer Institute (NCI)NIH	1	Aug 28, 2026	clinicaltrials
NCT06428396	Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)	active not recruiting	Phase 2	120	Merck Sharp & Dohme LLCINDUSTRY	9	Aug 28, 2026	clinicaltrials
NCT06765109	Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC(ALKAZAR)	recruiting	Phase 3	450	Nuvalent Inc.INDUSTRY	29	Aug 25, 2026	clinicaltrials
NCT06382948	Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.(ADELA)	recruiting	Phase 3	300	MedSIROTHER	9	Aug 24, 2026	clinicaltrials
NCT07620574	Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study	enrolling by invitation	Phase 3	5,000	ExelixisINDUSTRY	1	Aug 18, 2026	clinicaltrials
NCT07704658	Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors	recruiting	Phase 4	12	Rigel PharmaceuticalsINDUSTRY	1	Aug 10, 2026	clinicaltrials
NCT04280081	A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation(LIBRETTO-321)	active not recruiting	Phase 2	77	Eli Lilly and CompanyINDUSTRY	1	Aug 7, 2026	clinicaltrials
NCT05170204	A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)(HORIZON 1)	active not recruiting	Phase 3	68	Hoffmann-La RocheINDUSTRY	19	Aug 5, 2026	clinicaltrials
NCT01639508	Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity	recruiting	Phase 2	86	Memorial Sloan Kettering Cancer CenterOTHER	1	Aug 4, 2026	clinicaltrials
NCT03914300	Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer	active not recruiting	Phase 2	11	National Cancer Institute (NCI)NIH	1	Jul 31, 2026	clinicaltrials
NCT05663710	Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC	recruiting	Phase 1 / Phase 2	100	M.D. Anderson Cancer CenterOTHER	1	Jul 30, 2026	clinicaltrials
NCT03768063	A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study(IMbrella B)	active not recruiting	Phase 3	1,000	Hoffmann-La RocheINDUSTRY	24	Jul 24, 2026	clinicaltrials
NCT01087554	Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer	active not recruiting	Phase 1	249	M.D. Anderson Cancer CenterOTHER	1	Jul 16, 2026	clinicaltrials
NCT05722886	DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol(DETERMINE)	recruiting	Phase 2 / Phase 3	825	Cancer Research UKOTHER	1	Jul 1, 2026	clinicaltrials
NCT03032406	CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer	active not recruiting	Phase 2	53	Abramson Cancer Center at Penn MedicineOTHER	1	Jun 29, 2026	clinicaltrials
NCT04188548	A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer(EMBER)	active not recruiting	Phase 1	379	Eli Lilly and CompanyINDUSTRY	8	Jun 22, 2026	clinicaltrials
NCT05525858	KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II(KOSMOSII)	recruiting	—	1,000	Seoul National University Bundang HospitalOTHER	1	Jun 22, 2026	clinicaltrials
NCT05573126	Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer	recruiting	Phase 1 / Phase 2	95	Ellipses PharmaINDUSTRY	3	Jun 22, 2026	clinicaltrials
NCT05208047	(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors	recruiting	Phase 3	482	Cogent Biosciences, Inc.INDUSTRY	22	Jun 16, 2026	clinicaltrials
NCT05563220	Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer(ELEVATE)	active not recruiting	Phase 1 / Phase 2	435	Stemline Therapeutics, Inc.INDUSTRY	13	Jun 12, 2026	clinicaltrials
NCT06026410	KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors(FIT-001)	recruiting	Phase 1	300	Kura Oncology, Inc.INDUSTRY	5	Jun 8, 2026	clinicaltrials
NCT04514484	Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV	active not recruiting	Phase 1	8	National Cancer Institute (NCI)NIH	1	May 28, 2026	clinicaltrials
NCT04759911	Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer	active not recruiting	Phase 2	30	M.D. Anderson Cancer CenterOTHER	1	May 20, 2026	clinicaltrials
NCT05468359	Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients	recruiting	Phase 1 / Phase 2	64	St. Jude Children's Research HospitalOTHER	1	May 19, 2026	clinicaltrials
NCT03202940	A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC	active not recruiting	Phase 1 / Phase 2	16	Massachusetts General HospitalOTHER	1	May 8, 2026	clinicaltrials
NCT07062965	A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.	recruiting	Phase 3	400	PfizerINDUSTRY	27	May 6, 2026	clinicaltrials
NCT01187199	Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer	active not recruiting	Phase 1	278	M.D. Anderson Cancer CenterOTHER	1	Apr 16, 2026	clinicaltrials
NCT03157128	A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)(LIBRETTO-001)	active not recruiting	Phase 1 / Phase 2	857	Eli Lilly and CompanyINDUSTRY	16	Apr 16, 2026	clinicaltrials
NCT05987644	Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements(DURABLE)	recruiting	Phase 1 / Phase 2	56	Joshua PalmerOTHER	1	Apr 8, 2026	clinicaltrials
NCT03377023	Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer	active not recruiting	Phase 1 / Phase 2	66	H. Lee Moffitt Cancer Center and Research InstituteOTHER	1	Apr 2, 2026	clinicaltrials
NCT04963283	Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer	active not recruiting	Phase 2	48	University of Colorado, DenverOTHER	1	Mar 31, 2026	clinicaltrials
NCT03297606	Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)(CAPTUR)	recruiting	Phase 2	720	Canadian Cancer Trials GroupNETWORK	1	Mar 27, 2026	clinicaltrials
NCT05024214	Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors	recruiting	Phase 1 / Phase 2	170	3D Medicines (Sichuan) Co., Ltd.INDUSTRY	1	Mar 25, 2026	clinicaltrials
NCT04268550	Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)	active not recruiting	Phase 2	124	SWOG Cancer Research NetworkNETWORK	1	Mar 23, 2026	clinicaltrials
NCT04211337	A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer(LIBRETTO-531)	active not recruiting	Phase 3	291	Loxo Oncology, Inc.INDUSTRY	20	Mar 19, 2026	clinicaltrials
NCT04819100	A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)(LIBRETTO-432)	active not recruiting	Phase 3	152	Eli Lilly and CompanyINDUSTRY	32	Mar 4, 2026	clinicaltrials
NCT07435584	Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE)(EVER-RECODE)	not yet recruiting	Phase 1 / Phase 2	38	Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER	0	Feb 27, 2026	clinicaltrials
NCT07418879	A Real-world Study of Pralsetinib Combined With Leucogen in the Treatment of RET Fusion-positive NSCLC	not yet recruiting	N/A	25	Fudan UniversityOTHER	0	Feb 18, 2026	clinicaltrials

A study listed here tests a linked drug in a linked cancer; it does not necessarily select participants on this biomarker.

Approval rows flagged tumor-agnostic (3)

Associated cancers (10)

Drugs with predictive evidence (12)

Predictive evidence items (35)

Approvals mentioning the linked drugs (164)

Active trials (78)

Linked publications (30)